Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 27 | 35 | +8 |
| Shares | 16.3M | 16.7M | +368.7K (+2.3%) |
| Value | $54.1M | $124.9M | +$70.8M (+131.1%) |
New holders (9)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 683 Capital Management, LLC | 77,204 | $579.0K | 0.05% |
| Susquehanna International Group, LLP | 72,451 | $543.4K | 0.00% |
| Jane Street Group, LLC | 42,469 | $318.5K | 0.00% |
| Qube Research & Technologies Ltd | 28,351 | $212.6K | 0.00% |
| Omers Administration Corp | 26,164 | $196.2K | 0.00% |
| Goldman Sachs Group Inc | 23,965 | $179.7K | 0.00% |
| Hudson Bay Capital Management LP | 13,061 | $98.0K | 0.00% |
| Citigroup Inc | 1 | $8 | 0.00% |
| Motiv8 Investments LLC | 10 | $0 | 0.00% |
Sold out (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Wells Fargo & Company | 3 | $10 |